Eli Lilly and Company (LLY) is a global leader in healthcare innovation, specializing in discovering, developing, and ...
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
Eli Lilly and Company’s LLY shares declined 6.6% on Tuesday after the company lowered its sales guidance for full-year 2024 ...
Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...
Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, ...
Drug major Eli Lilly and Co. (LLY) on Tuesday trimmed its fourth-quarter revenue view below the Street estimates, but raised forecast ...
The shares of pharmaceutical giant Eli Lilly (LLY) are falling 5% today after the company preannounced lower-than-expected ...
JPMorgan analyst Chris Schott says Eli Lilly’s Q4 miss represents a buying opportunity as the company is positioned for strong growth in 2025. The company’s 2025 sales guidanc ...
David A. Ricks, Lilly’s CEO, attributed some of the shortfall to supply chain dynamics, noting that despite the setbacks, manufacturing capacity for incretin products is set to increase by at least 60 ...
Eli Lilly and Company’s LLY shares declined 6.6% on Tuesday after the company lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers.